Bringing a medical device to market is not just a technical and regulatory challenge. Effective engagement with regulatory bodies like the FDA require effective communication and strategy based on knowledge and discretion. Many early-stage teams underestimate how much success depends on how effectively they engage with FDA and how well they understand the regulatory landscape. This post highlights Rook’s recent FDA experiences that offer valuable lessons for in 3 areas: agency communication, the difference between the premarket and enforcement arms of the FDA, and the complexity of what can be perceived as a simple labeling change, such as prescription-use devices to home use, which significantly hamper potential success.
FDA is not your adversary, but it is also not your consultant. The quality of your communication directly impacts the clarity and usefulness of the feedback you receive.
Documentation: Make Structured Proposals Without Open Ended Questions
FDA reviewers are eager to partner with industry by providing valuable feedback. Q-Sub interactions or informal emails should be tailored to clearly outline a proposed approach with all necessary context and pre-emptively address FDA’s thinking, including risk-based nuances of the product type and legal frameworks the agency must operate under. Although FDA strives to provide specific feedback, open ended questions are strongly discouraged.
Best practices:
Lead with purpose: Clearly state what feedback is sought from FDA.
Provide just enough context: Include key assumptions, but avoid overloading with background.
Avoid ambiguity: If your question can be interpreted multiple ways, FDA will either answer narrowly or not at all.
Common mistake:
Founders often ask open ended questions like “How can I design a safe version of this device?”. FDA is not able to tell you what to do, only to provide feedback on a provided approach.
Teleconferences: Alignment, Not Brainstorming
Teleconferences (through Pre-Subs) are for confirming alignment, not discovering it in real time.
What works:
Submit a concise Pre-Submission package with clear questions supported by context necessary for FDA to:
- Provide specific feedback in written response prior to the meeting
- Be prepared in the teleconference to have a productive discussion
- Communicate further with sponsors informally to provide further support
What doesn’t work:
Introducing new topics not in the Pre-Submission package
Asking open-ended or questions that are designed to lock the FDA into a position
Concealing pertinent information that would affect FDA’s position
Key insight:
FDA’s most valuable feedback is often already in the written response. The teleconference is about reducing misinterpretation, not changing their position.
A critical mistake many entrepreneurs make is assuming “FDA” is one unified function. In reality, the premarket side and the enforcement side operate with different goals, incentives, and expectations.
Premarket (CDRH Reviewers)
Focus:
Safety and effectiveness (or substantial equivalence)
Adequacy of evidence
Risk-benefit profile
Mindset:
Forward-looking
Evaluating what you plan to do
Willing to provide feedback (within limits)
What matters:
Clinical and non-clinical data
Device description and intended use
Verification and validation evidence
Enforcement (Inspectors / Compliance)
Focus:
Whether you actually did what you said you would do
Whether your quality system is compliant and effective
Mindset:
Evidence-based and retrospective
Less flexible, more binary
Documentation-driven
What matters:
Records, not intent
Execution of your quality system
Traceability, complaints, CAPA, labeling controls
Why This Distinction Matters
Many assume that violations of the premarket pathways are allowable because the enforcement side has not taken action. For example, founders have asked “I see other competitors doing what appears against the law, how are they doing that?”. FDA is limited in resources although they are likely aware of these violations, priority is given to protect the public health.
Although this incongruency is noted and frustrating to founders, violations of the Food Drugs and Cosmetics Acts are still a significant violation that should not be entertained.
Bottom line:
The FDA Premarket teams strive to ensure new medical devices under their purview make it to market with a reasonable assurance of safety and effectiveness. FDA Enforcement teams address threats to public health by prioritizing active violations of the law.
One of the most underestimated regulatory challenges is expanding a device from prescription-use in a clinical setting to home use.
Why This Is Hard
Most devices are initially classified and cleared based on:
Controlled environments
Trained users (clinicians)
Managed risk conditions
When you move to home use, everything changes:
Users are untrained or minimally trained
Environments are uncontrolled
Risk of misuse increases significantly
This often breaks the original classification assumptions.
Why It Often Requires a De Novo
If your device’s original classification does not contemplate home use, FDA may determine that:
There is no appropriate predicate
The risk profile is fundamentally different
This can push you into a De Novo pathway, even if the core technology hasn’t changed.
Key drivers:
New use environment risks
Human factors and usability concerns
Labeling and instructions complexity
Need for additional validation (often including usability studies)
The Rise of Prescription Home Use
There is a growing middle ground emerging: prescription home use.
This pathway allows:
Use in the home
But under oversight of a healthcare provider
FDA has increasingly supported this approach because it:
Expands access to care
Maintains a level of control through prescription and clinical involvement
Strategic advantage:
Lower burden than full OTC (over-the-counter)
More flexibility than strictly clinical-use devices
Practical Implications for Founders
If home use is part of your long-term vision:
Plan for it early in your regulatory strategy
Build usability and human factors into your design inputs
Consider whether a staged approach makes sense:
- Initial clearance: prescription clinical use
- Expansion: prescription home use
- Future: potential OTC (if appropriate)
Trying to retrofit home use later is often more expensive and slower than designing for it upfront.
Success with FDA is not just about compliance, it’s about strategy and communication.
Clear, structured communication leads to better feedback
Understanding the difference between premarket and enforcement prevents downstream surprises
Anticipating classification challenges, especially around home use, can save years of rework
The most effective medical device companies treat regulatory not as a hurdle, but as a core design input from day one.